Table 3.
ELISA and neutralization assay results of 68 horse samples. (* not enough serum material for comp. ELISA, < 50µl)
| Laboratory sample no. | comp. WNV-ELISA S/N% | WNV-ELISA results | NT-ND50 (WNV lineage 2) | WNV-NT results | NT-ND50 (TBEV-Neudoerfl) | TBEV-NT results |
|---|---|---|---|---|---|---|
| ELISA and WNV-NT positive (n=42) | ||||||
| 33 | 14.19% | positive | 10 | weak positive | < 10 | negative |
| 44 | 12.28% | positive | 15 | weak positive | < 10 | negative |
| 53 | 6.18% | positive | 60 | positive | < 10 | negative |
| 54 | 4.98% | positive | 480 | positive | < 10 | negative |
| 58 | 6.35% | positive | 640 | positive | < 10 | negative |
| 59 | 5.09% | positive | 320 | positive | < 10 | negative |
| 64 | 4.73% | positive | 640 | positive | < 10 | negative |
| 68 | 4.94% | positive | 160 | positive | < 10 | negative |
| 69 | 4.87% | positive | 640 | positive | < 10 | negative |
| 71 | 4.98% | positive | 240 | positive | < 10 | negative |
| 72 | 4.83% | positive | 160 | positive | < 10 | negative |
| 75 | 5.90% | positive | 30 | positive | < 10 | negative |
| 88 | 5.53% | positive | 40 | positive | < 10 | negative |
| 96 | 5.97% | positive | 40 | positive | < 10 | negative |
| 97 | 4.91% | positive | 160 | positive | < 10 | negative |
| 105 | 5.77% | positive | 60 | positive | < 10 | negative |
| 107 | 4.73% | positive | 160 | positive | < 10 | negative |
| 108 | 4.67% | positive | 160 | positive | < 10 | negative |
| 123 | 7.86% | positive | 80 | positive | < 10 | negative |
| 124 | 4.81% | positive | 80 | positive | < 10 | negative |
| 128 | 4.15% | positive | 160 | positive | < 10 | negative |
| 131 | 3.88% | positive | 80 | positive | < 10 | negative |
| 146 | 8.79% | positive | 15 | weak positive | < 10 | negative |
| 149 | 4.31% | positive | 20 | positive | < 10 | negative |
| 158 | 4.04% | positive | 80 | positive | < 10 | negative |
| 160 | 3.78% | positive | 320 | positive | < 10 | negative |
| 166 | 4.55% | positive | 120 | positive | < 10 | negative |
| 187 | 4.63% | positive | 180 | positive | < 10 | negative |
| 208 | 6.09% | positive | 10 | weak positive | < 10 | negative |
| 217 | 7.84% | positive | 30 | positive | < 10 | negative |
| 228 | 4.44% | positive | 120 | positive | < 10 | negative |
| 232 | 10.92% | positive | 10 | weak positive | < 10 | negative |
| 288 | 4.48% | positive | 320 | positive | < 10 | negative |
| 289 | 9.16% | positive | 60 | positive | < 10 | negative |
| 292 | 5.09% | positive | 40 | positive | < 10 | negative |
| 297 | 5.35% | positive | 480 | positive | < 10 | negative |
| 312 | 5.12% | positive | 60 | positive | < 10 | negative |
| 313 | 4.92% | positive | 160 | positive | < 10 | negative |
| 330 | 7.98% | positive | 80 | positive | < 10 | negative |
| 336 | 4.18% | positive | 120 | positive | < 10 | negative |
| 337 | 4.44% | positive | 160 | positive | < 10 | negative |
| 343 | 7.08% | positive | 10 | weak positive | < 10 | negative |
| ELISA positive and WNV-NT negative (n=7) | ||||||
| 98 | 34.70% | positive | < 10 | negative | < 10 | negative |
| 106 | 26.64% | positive | < 10 | negative | < 10 | negative |
| 183 | 14.07% | positive | < 10 | negative | < 10 | negative |
| 230 | 23.58% | positive | < 10 | negative | < 10 | negative |
| 250 | 30.98% | positive | < 10 | negative | < 10 | negative |
| 295 | 25.88% | positive | < 10 | negative | < 10 | negative |
| 328 | 39.16% | positive | < 10 | negative | < 10 | negative |
| ELISA negative and WNV-NT positive (n=4) | ||||||
| 209 | 91.31% | negative | 30 | positive | < 10 | negative |
| 210 | 86.89% | negative | 120 | positive | < 10 | negative |
| 212 | 90.21% | negative | 10 | weak positive | < 10 | negative |
| 214 | 93.03% | negative | 320 | positive | < 10 | negative |
| Low volume ➔ no ELISA, WNV-NT positive (n=3) | ||||||
| 126 | n.d. | * | 80 | positive | < 10 | negative |
| 127 | n.d. | * | 60 | positive | < 10 | negative |
| 162 | n.d. | * | 60 | positive | < 10 | negative |
| Low volume ➔ no ELISA, WNV-NT negative (n=11+1 not evaluable) | ||||||
| 27 | n.d. | * | < 10 | negative | < 10 | negative |
| 76 | n.d. | * | < 10 | negative | < 10 | negative |
| 100 | n.d. | * | not evaluable, because of serum toxicity for cells | |||
| 125 | n.d. | * | < 10 | negative | < 10 | negative |
| 129 | n.d. | * | < 10 | negative | < 10 | negative |
| 130 | n.d. | * | < 10 | negative | < 10 | negative |
| 138 | n.d. | * | < 10 | negative | < 10 | negative |
| 139 | n.d. | * | < 10 | negative | < 10 | negative |
| 163 | n.d. | * | < 10 | negative | < 10 | negative |
| 179 | n.d. | * | < 10 | negative | < 10 | negative |
| 180 | n.d. | * | < 10 | negative | < 10 | negative |
| 186 | n.d. | * | < 10 | negative | < 10 | negative |